Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Identifying genes that increase the risk of bowel or other cancers allows us to offer preventative measures, such as removing tumours at an early stage. A better understanding of how and why cancers grow also helps develop improved treatments.

Q: What is the contribution of genetics to colorectal cancer?

Ian Tomlinson: Cancers grow in two ways owing to genetics; the first of those is that particular genes may put certain people at higher risk of colon cancer, as indeed other cancer types. Secondly, cancers principally develop because of genetic changes that they acquire as they come from a normal piece of tissue all the way through to benign lesions, or polyps in our case, through to a fully blown aggressive cancer. Those particular changes are what drive cancer growth.

Q: How does your research help reduce the burden of colorectal cancers?

IT: A lot of our research focuses on identifying genes that increase colon cancer risk. If we can do that, as we have done in the past, then the people who are at increased risk can have special measures to prevent colon cancer such as colonoscopy - an examination using a telescope of the large bowel – and by doing that we can remove tumours either before they become malignant or at the early stage of malignancy, therefore saving people lives.

Q: How is this information used in the clinic?

IT: We see people in the cancer genetics clinic, either who have referred themselves because they are concerned about their own history of cancer or their family history, or where a GP or surgeon has referred them. We evaluate the family history and do genetic testing on selected people to see if they have a high risk cancer gene and then we recommend measures to prevent cancer as far as we possibly can in those who are at increased risk.

Q: What are some of the most important lines of research to develop in the last five to ten years?

IT: The ability to identify cancerous genes has increased because technologies have allowed us to study large numbers of people and we have identified not only additional high risk genes but also genes that are present in the general population that will either reduce or increase your bowel cancer risk. Increasingly, we can look at the cancers themselves because they have genetic changes that cause them to grow and we can use those to classify cancers and also to suggest treatments that in some cases that may improve the management of those people.

Q: Why does your research matter and why should we put money into it?

IT: Ultimately cancer is best dealt with by prevention and we know that we have identified some of the genes that predispose to bowel cancer, but if we can get closer to a complete picture, we can better target the screening based on that genetics and other factors such as lifestyle. Our research also deals with gaining a better understanding of how cancers grow and why. I strongly believe that our treatments for cancer and the management of cancer patients must be informed by that basic understanding of how cancers develop.

Q: How does your research fit into translational medicine within the Department?

IT: By its very nature, because we are working on identifying cancer genes, there is almost always a translational component. We have already identified five or six cancer genes that are now tested worldwide, and helped those patients who have inherited those genes to prevent them from developing cancer.

Ian Tomlinson

Ian Tomlinson, Professor of Molecular and Population Genetics at the Wellcome Trust for Human Genetics, works on the identification of genes that predispose to colorectal and other cancers. His research focuses on the relative importance of selection and genomic instability.

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

Cancer Ex-faculty podcasts Global Health

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

Cancer Ex-faculty podcasts

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

Anna Gloyn: Genetics and Diabetes

Ex-faculty podcasts Genetics

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

David Jackson: The Lymphatic System in Immunity and Cancer

Cancer Ex-faculty podcasts

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

Cancer Ex-faculty podcasts

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Erika Mancini: Chromatin Remodelling

Ex-faculty podcasts Genetics

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Ex-faculty podcasts Genetics

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Ex-faculty podcasts Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Patrick Pollard: Cancer Metabolism

Cancer Ex-faculty podcasts

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Claire Palles: Gastrointestinal cancers

Genetics

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.